Internal Medicine, Endocrinology, Diabetes, & Metabolism · Saginaw, MI
NPI
1326302712
Since 2012
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
4801 McLeod Dr E
Saginaw, MI, 48604
Phone (989) 607-0809
Groups this clinician bills Medicare through
Medicare paid, 2024
$187K
3,190 services
Medicare patients, 2024
641
Average age 69
Drug cost, 2024
$6.8M
9,326 prescriptions
Company payments, 2025
$11K
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amer Issa was code 99214 (office e&m - established), 1,202 times for 487 patients. In total Amer Issa billed 3,190 services in 12 codes, and Medicare paid $187K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-11-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,202 | 487 | $81.84 | $98K |
| 99232 Hospital E&M - Subsequent | Facility | 694 | 125 | $56.56 | $39K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 559 | 339 | $11.77 | $6,578 |
| 95251 Test - Miscellaneous | Office | 359 | 148 | $22.90 | $8,220 |
| 99222 Hospital E&M - Initial | Facility | 177 | 137 | $91.66 | $16K |
| 99204 Office E&M - New | Office | 165 | 165 | $104.98 | $17K |
| 99213 Office E&M - Established | Office | 18 | 13 | $48.18 | $867 |
By year: 2022 $92K for 1,335 services; 2023 $155K for 2,389 services; 2024 $187K for 3,190 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 133 | 88 | $9.35 | $1,244 |
Medicare prescription drug claims, 2024
In 2024, the drug Amer Issa prescribed most often to Medicare patients was Ozempic (Semaglutide), with 1,156 prescriptions and refills. In total Amer Issa wrote 9,326 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 1,156 | 1,731 | 246 | $1.6M |
| Mounjaro Tirzepatide | 1,089 | 1,363 | 219 | $1.4M |
| Levothyroxine Sodium Generic | 703 | 1,818 | 209 | $9,910 |
| Jardiance Empagliflozin | 652 | 1,493 | 188 | $833K |
| Metformin Hcl Generic | 403 | 1,077 | 131 | $3,981 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 384 | 910 | 133 | $50K |
| Novolog Flexpen Insulin Aspart | 291 | 532 | 106 | $86K |
| Topiramate Generic | 251 | 655 | 97 | $4,498 |
| Humalog Kwikpen U-100 Insulin Lispro | 249 | 541 | 86 | $79K |
| Pioglitazone Hcl Generic | 227 | 639 | 76 | $4,641 |
| Methimazole Generic | 223 | 584 | 74 | $3,640 |
| Glipizide Generic | 221 | 591 | 70 | $2,998 |
| Farxiga Dapagliflozin Propanediol | 219 | 430 | 51 | $213K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 169 | 341 | 73 | $17K |
| Novolog Insulin Aspart | 144 | 188 | 32 | $27K |
Brand drugs: 5,832 claims; generic drugs: 2,889 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amer Issa $11K ($11K in general payments such as food, travel and fees) from 28 companies. The largest payer was Novo Nordisk Inc with $9,040.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 31 | $9,040 |
| Tandem Diabetes Care, Inc. TNDM | 10 | $199 |
| Insulet Corporation PODD | 9 | $183 |
| Lilly USA, LLC LLY | 11 | $167 |
| Abbvie Inc. ABBV | 9 | $165 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $157 |
| Corcept Therapeutics CORT | 8 | $156 |
| Amgen Inc. AMGN | 10 | $149 |
| Dexcom, Inc. DXCM | 5 | $146 |
| Abbott Laboratories ABT | 7 | $139 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.